

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

JACOBIO TO PRESENT CLINICAL DATA OF GLECIRASIB IN COMBINATION WITH JAB-3312 AT THE 2023 ESMO CONFERENCE

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company will present the clinical data of Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in the form of proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from October 20, 2023 to October 24, 2023. The presentation details are as follows:

Presentation Number: 4838

Title: Glecirasib (KRAS G12C inhibitor) in Combination with JAB-3312 (SHP2 inhibitor) in Patients with KRAS G12C Mutated Solid Tumors

Studies have shown that SHP2 inhibitor is one of the most optimal partners for KRAS G12C inhibitor in non-small cell lung cancer (NSCLC). The Company previously presented preclinical results of the above combination at the 2022 ESMO Asia Congress, showing that the combination of Glecirasib (JAB-21822) and JAB-3312 could synergistically inhibit tumor growth in multiple KRAS G12C inhibitor-resistant models. This suggests that the combination of Glecirasib and JAB-3312 may overcome adaptive resistance to KRAS G12C inhibitor in cancer patients.

ESMO Congress 2023 will be held in Madrid, Spain, from October 20, 2023 to October 24, 2023. For more information, please visit the official website of the ESMO: <https://www.esmo.org/>

About Glecirasib

Glecirasib is Jacobio’s novel KRAS G12C inhibitor independently developed by the Company. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial to treat non-small cell lung cancer (NSCLC) in China, a monotherapy study for STK11 co-mutated NSCLC in the front-line setting; combination therapy trials with SHP2 inhibitor JAB-3312, anti-PD-1 monoclonal antibody and Cetuximab.

About JAB-3312

JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) and JAB-3312 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, July 21, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.